Ultragenyx and Kyowa Kirin announce burosumab receives positive CHMP opinion
Kyowa Hakko Kirin and Ultragenyx Pharmaceutical announced the EMA's Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending the conditional marketing authorization of burosumab, an anti-FGF23 human monoclonal antibody, for treatment of XLH. December 15, 2017